HarmResearch gave the following presentations at the 2018 Annual Meeting of the American Psychiatric Association (APA):
Monday, May 6th, 2018 Symposium
Novel Approaches in Assessing, Monitoring, Preventing, and Treating Suicidality
Date: Monday, May 6th, 2018
Time: 1 pm to 4 pm
Location: Room 1E11, Javits Convention Center, New York, NY
Symposium Number: 1095
1. A Review of Utah’s Approach to Successful Suicide Prevention in Schools
Dr. Gregory Hudnall: Founder Hope4Utah
Dr. Hudnall will share the “hope squad” model: a school based peer to peer suicide prevention program that helped reduce youth death by suicide by 25% in Utah.
2. A Review of Novel Legislative Approaches to Successful Suicide Prevention in Utah
Utah State & Representative Steve Eliason
Participants will hear from State Legislator Steve Eliason on how Utah has a multi-dimensional, legislative approach to suicide prevention.
3. Zero Suicide in Texas: Creating a Statewide Suicide Safer Care System
Jenna Heise MA, BC-DMT, NCC, Texas State Suicide Prevention Coordinator
This presentation discusses the process by which the “Zero Suicide” initiative was implemented in the state of Texas. It provides an overview of the 7 basic components of the “Zero Suicide” initiative and summarizes the tools and resources available for this comprehensive approach.
4. The Pharmacological Treatment of Suicidality
Dr. David V. Sheehan, MD, MBA, Distinguished University Health Professor Emeritus at University of South Florida College of Medicine
There is increasing evidence that suicidality has a genetic component that can be transmitted independently of transmission of depression and other psychiatric disorders. Suicidality may be a group of separate Axis I disorders, that need separate pharmacologic treatments. The presentation will provide a phenotypic classification of suicidality disorders and will overview recent advances in specific anti-suicidality medication treatments.
5. The Graphic Display of Quantitative Suicidality Data: S-Plots
Jennifer M. Giddens, BA, University of South Florida College of Arts and Sciences
Regulatory agencies, pharmaceutical companies, clinical research organizations, data safety monitoring boards, medical directors of health care organizations, and medical safety officers are challenged with the difficulty of summarizing the suicidality status of patients under their care in a simple, clear manner. This presentation provides an overview of several methods of graphically displaying quantitative suicidality data captured from the S-STS. These S-Plots (for Suicidality Plots) display the data both for groups of patients and individual patients over time. The presenter will review the interpretation of these S-Plots, to identify patients at higher risk, and provide a method to monitor the status of these patients over time.
6. Panel Discussion: Questions and Answers
3 Hour Symposium
10 minutes Introduction
25 minutes for each presentation
30 minutes for Panel Discussion
1. Understand the importance of peer relationships in youth suicide prevention.
2. Understand the value of legislative initiatives in the prevention of suicidality.
3. Understand the process of implementing a state-wide program of suicidality assessment.
4. To be aware of the medications being used or studied for the treatment of suicidality.
5. Understand the importance of the graphic display of quantitative suicidality data (S-Plots) and their use in to identify patients at higher risk, and provide a method to monitor the status of these patients over time.
How to Cite:
Sheehan DV, Giddens JM, Hudnall G, Eliason S, Heise J. Novel Approaches in Assessing, Monitoring, Preventing, and Treating Suicidality. Presidential Symposium. Annual Meeting, American Psychiatric Association (APA), New York City, NY, May, 6, 2018.
Wednesday, May 8th, 2018 Poster
The Graphic Display of Quantitative Suicidality Data: S-Plots
Jennifer M Giddens BA 1, 2
David V Sheehan MD, MBA, DLFAPA 1, 2, 3
1 Harm Research Institute, Tampa, FL, USA
2 Tampa Center for Research on Suicidality, Tampa, FL, USA
3 University of South Florida College of Medicine, Tampa, FL, USA
Date: Wednesday, May 8th, 2018
Time: 10 am to Noon
Location: Room 1E11, Javits Convention Center, New York, NY
Poster Number: P7-148
Background: Regulatory agencies, pharmaceutical companies, clinical research organizations, data safety monitoring boards, medical directors of health care organizations, and medical safety officers are challenged with the difficulty of summarizing the suicidality status of patients under their care in a simple, clear manner. Currently, data collected using a dimensional scale are reduced to the categorical system at the completion of a study. Suicidality data is currently organized and reviewed in complex tables, reflecting these categories, with a resultant loss of sensitivity and the risk of delayed detection, or of detection errors. Linking such data to study stopping rules is a complex multistep series of tasks, fraught with potential errors. In the interest of reducing error, speeding detection, protection of patients, clarity of data presentation and display, there is a need for a more efficient, clear, and simple system to display suicidality data.
Methods: We explored and reviewed graphic displays of quantitative data in other medical and scientific disciplines to find suitable models. The selection criteria included simplicity, clarity, the ease of interpretation of the data, and how appropriate the displays would be for suicidality data, collected using a dimensional suicidality tracking scale. We applied a variety of graphic displays to a prospectively collected dataset using the Sheehan-Suicidality Tracking Scale (S-STS). The final displays are the result of this iterative process.
Results: Suicidality-Plots (S-Plots) display the data for groups of patients and for individual patients over time. Interpretation of these S-Plots can quickly identify patients at higher risk, and provide a method to monitor the status of patients within a large sample over time. Interpretation of S-Plots can quickly identify the overall status of suicidality in the study over time in relation to the study stopping rules. Graphic display of quantitative suicidality data can be used to quickly visually identify individual patients at high risk, the disposition of all patients in a healthcare setting or clinical trial, and whether a clinical trial should be halted because of treatment-emergent suicidality. These S-Plots are customizable for the needs of different clinical trials and settings. A computer-generated version of these S-Plots is in development. It is designed to generate e-mails or phone alerts to site investigators and sponsors for subjects deemed at imminent risk, and who need immediate attention.
Conclusion: Use of S-Plots may reduce the potential medico-legal hazards from either the delayed analysis or delayed detection of suicidality in safety data, and the risk to patients in research trials and clinical settings.
Following this presentation, participants will be:
1. Be familiar with graphical approaches to the display of quantitative suicidality data in clinical research trials and clinical settings
2. Better able to understand, interpret, and analyze suicidality data displayed in S-Plots
1. Tufte E, Graves-Morris P. The visual display of quantitative information.; 1983.
2. Amit O, Heiberger RM, Lane PW. Graphical approaches to the analysis of safety data from clinical trials. Pharmaceutical Statistics. 2008 Jan 1;7(1):20-35.
How to Cite:
Giddens JM, Sheehan DV. The Graphic Display of Quantitative Suicidality Data: S-Plots. Poster. Annual Meeting, American Psychiatric Association (APA), New York City, NY, May, 8, 2018.